Levi & Korsinsky Notifies Shareholders of Novo Nordisk A/S(NVO) of a Class Action Lawsuit and an Upcoming Deadline
NEW YORK, NY / ACCESS Newswire / March 11, 2025 / If you suffered a loss on your Novo Nordisk A/S (NYSE:NVO) investment and want to learn about a ...
Roche hires Novo Nordisk executive amid obesity drug push, Bloomberg reports
Roche (RHHBY) has hired a senior executive from Novo Nordisk (NVO) as it prepares to enter the competitive market for obesity drugs, ...
Novo Nordisk Shares Fall After Latest CagriSema Obesity Drug Trial Results
New trial data showed the drug helped obese or overweight type 2 diabetics lose an average 15.7% of their weight, when an ...
Roche Hires Novo Executive to Help Push Into Obesity Drug Market
Roche Holding AG hired a senior executive from rival Novo Nordisk A/S as the Swiss drugmaker prepares to enter the ...
Investor's Business Daily on MSN1d
Novo Nordisk Dives 9%. Why Eli Lilly Now Has The Upper Hand.
Novo Nordisk stock tumbled Monday after its experimental weight-loss drug failed to top its rival from Eli Lilly in a Phase 3 study.
MarketBeat on MSN1d
Despite Challenges Novo Nordisk Plans to Crush GLP-1 Competitors
Novo Nordisk A/S (NYSE: NVO) has declared that its GLP-1 drugs for chronic obesity, under the brands Ozempic and Wegovy, are ...
STAT1d
Novo Nordisk shares drop after next-gen obesity drug disappoints in diabetes trial
Novo Nordisk reported results on its next-generation obesity drug in diabetes patients, including data on weight loss that ...
Novo Nordisk shares fall on weight-loss drug trial
Novo Nordisk released the results from its late-stage trial of CagriSema on Monday. It showed that patients on the highest dose of the drug lost 15.7% of their weight.
Novo Nordisk shares fall 6.3% after latest trial results for its next-generation weight loss drug
Shares of Novo Nordisk fell sharply on Monday, after the firm published results from the latest clinical trial of its ...